

# L3.

## Drug therapy of heart failure

### [1] & [2]

EDITING FILE

COLOR INDEX :

- MAIN TEXT
- IMPORTANT
- GIRL'S SLIDES
- BOY'S SLIDES
- NOTES
- EXTRA





فشل قلب المريض وودّه يرجع  
خلِ بري لود وأفتر لود صيدك  
وبعدين الدجكسن خله يفزع  
يخلي قبضته تشبه حديدك

علي العبدالعظيم



# Objectives:

- Describe the different classes of drugs used for treatment of acute & chronic heart failure & their mechanism of action.
- Understand their pharmacological effects, clinical uses, adverse effects & their interactions with other drugs.



First video  
Intro min 4:20  
Left heart failure min 8:33  
Heart sounds min 15:00  
Right heart failure min 17:00  
Pathological classification min 25:00  
Pathophysiology min 28:30



Second videowatch about symptoms  
Intro first 10 mins  
Diagnosis min 10:00  
Brain bridge reflex min 20:00  
Conductivity min 21:00  
Echocardiography min 22:30  
ECG min 30:30  
Use of digoxin min 40:30  
Atrial fibrillation min 50:30  
Contraindications min 56:00  
Toxicity min 1:20:00  
Cardiac and non cardiac 1:24:30



Third video  
Intro first 5 mins  
PDE inhibitors min 6:00  
ACEI & Diuretics min 17:00  
Spironolactone min 21:00  
Inotropes min 24:00  
Vasodilators min 26:00  
Beta blockers min 30:00  
Cardiogenic pulmonary edema & Loop diuretics min 37:00  
Nitroglycerine min 49:00

# What is Heart Failure?

## Definition:

Inability of the heart to maintain an adequate cardiac output to meet the metabolic demands of the body. (progressive)

## Causes (acute or chronic)

- Heart valve disorder.
- High blood pressure.
- Disorder of coronary arteries.  
Disease in coronary arteries will decrease the blood flow and blood supply to the heart which leads to decrease in O<sub>2</sub> supply to the heart, and cause heart failure
- Cardiomyopathy.
- Abnormal heart rhythm


the causes could be due to

- Extrinsic factors : factors that out of the heart
- intrinsic factors: factors that related to the heart itself

Extrinsic factors: High BP - Disorder of coronary arteries .  
Rest of the causes are Intrinsic factors.

## Symptoms

- Tachycardia.
- Cardiomegaly. (Abnormal enlargement of heart)
- Decreased exercise tolerance. (Rapid Fatigue)
- Peripheral edema. (Right-sided heart failure)  
Due to poor circulation
- Dyspnea (Pulmonary congestion). (Left-sided heart failure)



# Pathophysiology of Congestive Heart Failure (CHF)


When there is low CO it will cause the heart to undergo compensatory responses:



**Factors affecting cardiac output and heart failure:**

- 1- Preload
- 2- Afterload
- 3- Cardiac contractility

الإدوية التي يتأخذها كلها راجح تأثر على هذه العوامل  
442






# Drugs used in treatment of heart failure



The ultimate goal of therapy:

- 1- Alleviate symptoms
- 2- Slow disease progression
- 3- Improve survival



Site of action



## |- Drugs that decrease **preload (venous return)**

1- Diuretics (used to decrease accumulation of fluid).	Chlorothiazide, Furosemide
2- Aldosterone antagonists	Spironolactone, Eplerenone
3- Venodilators	Nitroglycerine, Isosorbide dinitrate

## ||- Drugs that decrease **afterload (peripheral resistance)**

1- Arteriodilators	Hydralazine
--------------------	-------------

## |||- Drugs that decrease both **preload and afterload (combined arterio- & venodilators)**

1- Angiotensin converting enzyme (ACE) inhibitors	Captopril, Enalapril, Ramipril
2- Angiotensin receptor antagonists	Losartan, Valsartan, Irbesartan
3- $\alpha_1$ -adrenoceptor antagonists	Prazosin
4- Direct vasodilators	Sodium nitroprusside
5- Beta blockers	Bisoprolol, Metoprolol, Carvedilol, Nebivolol

#### IV- Drugs that increase **heart contractility**

1- Cardiac glycosides (digitalis)	Digoxin
2- (selective) $\beta$ - adrenoreceptor agonists	Dobutamine
3- Phosphodiesterase inhibitors	Milrinone, Enoximone, Vesnarinone

#### $\beta$ - adrenoceptors blockers in heart failure

Second generation	Bisoprolol, Metoprolol
Third generation	Carvedilol, Nebivolol

#### New drugs for heart failure

Natriuretic peptides	Nesirtide
Calcium sensitisers	Levosimendan

# I- Drugs that decrease preload

1

Diuretics

2

Aldosterone antagonists

3

Venodilators

## 1- Diuretics (↓ Congestion & edema)


Drug	Chlorothiazide	Furosemide (lasix)
Subgroup	Thiazides	Loop diuretics

### M.O.A in HF

-Reduce water and salt retention (↑ excretion) → decrease ventricular preload and venous pressure → reduction of cardiac size → improvement of cardiac performance.

-different diuretics function on different parts of a nephron of the kidney, and because each part is responsible for a certain percentage of salt & water excretion, the part a diuretic drug functions on determines how strong it is (it's efficacy). Therefore, a drug that works on a part that secretes 60% of salt & water is strong, but a drug that works on a part that secretes 5% is weak.

-A nephron is divided into 4 parts:  
proximal convoluted tubule → loop of henle → thick ascending limb of loop of henle → distal convoluted tubule.




Cause HyperCalcEmia → Thiazide diuretics 

Cause HyperKalEmia → K<sup>+</sup> Sparing diuretics

**Important**



<b>MOA</b>	<p>Works on distal convoluted (secretion of 5% of water &amp; salt).</p> <p>Not a strong diuretics (mild).</p>	<p>Works on Na-Cl concentrations in cells of the thick ascending limb of loop of henle (secretion of 25% of water &amp; salt) (5 times stronger than chlorothiazide).</p> <p>A potent diuretic.</p>
<b>Use</b>	<p> -First line agent in heart failure therapy. (to control edema)</p> <p>-Used in volume overload (Pulmonary and/or peripheral edema). (↓ Pulmonary congestion).</p> <p>-Used in mild congestive heart failure. (mild because it works on the part that secretes 5% of water and salt) بالبداية فقط لما تكون حالة المريض مستقرة وليست طارئة. It is commonly used with losartan and valsartan</p>	<p>-loop is better than thiazide in HF, used in emergency &amp; acute case</p> <p>-Used for immediate reduction of pulmonary congestion (edema) &amp; severe edema associated with:</p> <p>1-Acute heart failure</p> <p>2- Moderate &amp; severe chronic failure.</p> <p>- ↑ urine output, cause hypotension and hypokalemia</p>
<b>ADRs</b>	<p>- ↑ urine output, cause hypotension and hypokalemia</p>	

## 2- Aldosterone antagonists

<b>Drugs</b>	<b>Spirolactone (most famous)</b>	<b>Eplerenone (better)</b>
<b>MOA</b>	<p>Non-selective antagonist of aldosterone receptor. (non-selective: it can bind to other steroid hormones receptors, like "gynecomastia" ممكن يسبب تندي. androgen &amp; estrogen)</p> <p>A potassium sparing diuretic (K<sup>+</sup> is not-excreted → hyperkalemia)</p> <p>.so it's drug of choice when the patient has hypokalemia</p>	<p>A new selective Aldosterone receptor antagonist (does not inhibit other hormones such as estrogen &amp; androgens).</p>

Use	Improves survival in advanced heart failure	Indicated to improve survival of stable patients with congestive heart failure
<b>3- Venodilators</b>		
Drug	<b>Nitroglycerine</b>	<b>Isosorbide dinitrate</b>
PK	-Used IV. -Used in emergency.	
M.O.A	- $\uparrow$ cGMP in smooth muscles of vessels $\rightarrow$ Dilates venous blood vessels & reduce preload.	
Use	-Used IV for severe heart failure when the main symptom is dyspnea due to pulmonary congestion and edema. -Dyspnea is often a symptom associated with increased preload. (Venodilators are used in Angina too).	
<b>II- Drugs that decrease afterload</b>		
<b>Arteriodilators</b>		
Drug	<b>Hydralazine</b> حيدر الحزين	
M.O.A	Direct relaxation of vascular smooth muscle cells in resistance Arterioles $\rightarrow$ reduce peripheral vascular resistance	
Use	Used when the main symptom is rapid fatigue due to low cardiac output	
ADRs	Hypotension, lupus- like syndrome	



(mainly used in hypertension & HF)

# III- Drugs that decrease both Afterload & preload

1

**ACE Inhibitors**  
(Angiotensin converting enzyme )

2

**ARBs**  
(Angiotensin receptors blockers )

3

**$\alpha$ -Adrenoceptors blockers**

4

**Direct acting vasodilators**

5

**$\beta$ - blockers**

## Angiotensin converting enzyme (ACE) inhibitors (first line therapy).

Drug	<b>Captopril (causes dry cough, must not take it with losartan)</b>	<b>Enalapril</b>	<b>Ramipril</b>
Use	<p>-Considered as first-line drugs for chronic heart failure along with diuretics. -First-line drugs for hypertension therapy.</p>		
PK	<p>-Rapidly absorbed from GIT after oral administration. -Food reduce their bioavailability. Therefore, the patient is advised to take these medication in an empty stomach or 2 h b4 the meal</p>		
PK	-	<p>-<b>prodrugs</b>, converted to their <u>active</u> metabolites in liver. -Have long half-life &amp; given once daily.</p>	

M.O.A

-inhibiting ACE, will achieve the opposite of all angiotensin II normal actions in his results in increase in CO.

Helpful video:



-plasma protein Angiotensinogen (synthesized in the liver) is converted to angiotensin I by renin (enzyme in juxtaglomerular cells of the kidney & then released in the circulation). ACE enzyme converts Angiotensin 1 → Angiotensin 2


RAAS System Effects


Angiotensin II effects:

- extremely powerful vasoconstrictor (constriction of arterioles)
- ↑ total peripheral resistance → ↑ arterial pressure (mild constriction of veins)
- ↑ venous return
- stimulating the secretion of aldosterone (sodium and water retention).
- stimulating the secretion of Vasopressin (antidiuretic hormone) → water retention
- stimulating the sympathetic nervous system
- causes hypertrophy of vascular & cardiac cells & increases synthesis & disposition of collagen by cardiac fibroblast (remodeling).

EXTRA \*text in red is in slides

- Increased renin in the body is mainly responsible for cardiac & vascular remodeling.
- ACE (kininase II) is also essential for the breakdown of bradykinin (additive vasodilation effects).



<b>Pharmacological actions</b>	<ul style="list-style-type: none"> <li>-Decrease peripheral resistance (Afterload) (arteriodilation).</li> <li>-Decrease venous return (preload) (venodilation).</li> <li>-Decrease sympathetic activity.</li> <li>-<b>Inhibit cardiac and vascular remodeling associated with chronic heart failure (protect to the heart) → decrease in mortality rate.</b></li> </ul>
<b>ADRs</b>	<ul style="list-style-type: none"> <li>-<b>Acute renal failure, especially in patients with renal artery stenosis.</b></li> <li>-<b>Hyperkalemia</b>, especially in patients with renal insufficiency or diabetes. (Aldosterone will increase Na retention and K excretion so when we inhibit it that will lead to increase in K in our body. And when the patient has renal insufficiency the K will increase more because he has already poor excretion of K).</li> <li>-<b>Severe hypotension</b> in hypovolemic patients → <b>hypovolemic due to diuretics, salt restriction or gastrointestinal fluid loss</b> e.g. severe vomiting or diarrhea.</li> <li>-<b>Dysgeusia</b> (reversible loss or altered taste). (reversible: if we stop the drug the side effects will disappear).</li> <li>*the last 2 ADRs are associated with Bradykinin accumulation (<b>important</b>):-</li> <li>-<b>Dry cough sometimes with wheezing because of Bradykinin accumulation</b>  <b>important</b></li> <li>-<b>Angioneurotic edema</b> (swelling in the nose, throat, tongue, larynx). <small>if in the layrnx this is a severe case</small></li> </ul>
<b>Contraindications</b>	<ul style="list-style-type: none"> <li>-During the second and third trimesters of pregnancy (not recommended for the first trimester too). (due to high risk of: fetal hypotension, renal failure, and malformation)</li> <li>-Renal artery stenosis (will cause renal failure).</li> </ul>


# III- Drugs that decrease both Afterload & preload

## Angiotensin receptor blockers (ARBs)

Used if ACE inhibitors are contraindicated or intolerated. (Just affect receptor not production)

Drug	<u>Losartan</u>	<u>Valsartan</u>	<u>Irbesartan</u>
------	-----------------	------------------	-------------------

M.O.A	<ul style="list-style-type: none"> <li>- <b>Block angiotensin 1 (AT1) receptors.</b> Less ADRs due to bradykinin accumulation</li> <li>- <b>Decrease action of angiotensin II.</b></li> <li>- AT1 mediates most of the known actions of Ang &amp; predominate in vascular smooth muscle → renal sodium reabsorption, vasoconstriction, cell growth and proliferation (remodeling).</li> <li>- AT2 → natriuresis, vasodilation, anti proliferation.</li> </ul>		
-------	---	--	--



## α-Adrenoceptor BLOCKERS

Drug	<u>Prazosin</u>
------	-----------------

M.O.A	<ul style="list-style-type: none"> <li>- Blocks α- receptors in arterioles and venules.</li> <li>- Decrease both afterload &amp; preload.</li> </ul>
-------	--

# Direct acting vasodilators (by ↑ cGMP)

drug	Sodium nitroprusside
P.K	- Acts immediately and effects lasts for 1-5 min. (it doesn't affect the receptors it acts directly on blood vessels , so the action will be very fast)
Uses	- Given I.V. for acute or severe heart failure.

## 4-Drugs that increase contractility

- 1 Cardiac glycosides (digitalis)
- 2  $\beta$ -Adrenoceptor AGONIST
- 3 Phosphodiesterase - III inhibitors

## Cardiac glycosides (digitalis)

drug	Digoxin
M.O.A	<p><b>Inhibits Na<sup>+</sup> / K<sup>+</sup> ATPase enzyme (the sodium pump)→</b> <b>-Increases the force of myocardial contraction (+ve inotropic effect).</b></p> <p>Normal function of Na/K pumps -number 1 in the picture - :</p> <ol style="list-style-type: none"><li>1. Na/K pump, works during repolarization: K in, Na out ( against gradient)</li><li>2. Na/Ca pump : Ca out, Na in</li></ol> <p>Abnormal function of pumps due to presence of Digoxin :</p> <ol style="list-style-type: none"><li>1. Blocked Na/K channels</li><li>2. Reversed Na/Ca pumps (Na out ,Ca in)</li></ol>

<b>Uses</b>	- Congestive heart failure <b>- has narrow therapeutic index</b> ONLY if patient has decrease in contractility (438).	
<b>ADRs</b>	<b>Cardiac:</b> digitalis-induced arrhythmias: - Extrasystoles. - Coupled beats (Bigeminal rhythm). - Ventricular tachycardia or fibrillation. - Cardiac arrest (toxic dose).	<b>Non-cardiac:</b>  -GIT anorexia (loss of appetite), nausea, vomiting, diarrhea -CNS: headache, visual disturbances, drowsiness. <small>visual disturbances: Can see halos in light</small>
<b>Factors that Increase its toxicity</b> (check for ion balance before starting therapy)	<ol style="list-style-type: none"> <li>1. Renal diseases            (because it's excreted through it &amp; because the kidney is responsible for ion balance in the body and any imbalance in ions will affect digoxin toxicity).</li> <li>2. Electrolyte disturbances:           <ul style="list-style-type: none"> <li>• Hypokalemia ( ↓ K so easier binding of digoxin, could happen by taking non-K sparing diuretics ).</li> <li>• Hypomagnesemia Mg is cofactor of sodium pump so if it not present the pump won't function achieving what digoxin is already trying to achieve).</li> <li>• Hypercalcemia ( ↑ ↑ intracellular Ca).                it already causes calcium influx so having too much calcium entering the cells with cause problems</li> </ul> </li> </ol>	

## β-Adrenoreceptor Agonist

<b>drug</b>	<b>Dobutamine</b>
<b>M.O.A</b>	<b>Selective β1 agonist.</b> Remember: You have one heart so β1, And you have two lungs so β2



Uses

Treatment of acute heart failure in cardiogenic shock

## Phosphodiesterase-III inhibitors ( ↑ cAMP)

DRUG

Milrinone

Enoximone  
Vesnarinone

M.O.A

**Inhibit phosphodiesterase -III** (cardiac & B.vessels) → ↑ cAMP.  
- ↑ cAMP in cardiomyocytes → increases cardiac contractility.  
- ↑ cAMP in vascular smooth muscles → dilatation of arteries & veins  
(reduction of preload & afterload).

Extra explanation from the doctor [click here](#)

Uses

-Used only IV for management of acute heart failure.  
-Not safe for effective in the longer (>48 hours) treatment of patients with heart failure.

New drugs in clinical trials.

ADRs

- Hypotension and chest pain (angina)  
( so it's not use at more than 2 days )

-

Chemical interactions

- Furosemide (Diuretic drug) shouldn't be administered in IV lines containing milrinone due to formation of a precipitate.


فادوائين الـ 2 مايشغلون لانه لازم الدواء يكون ذائب في المحلول وليس عنده سب  
Precipitate. راسب كيميائي  
DI is either

1- PK, 2- PharmacD, 3- Chemical  
Extra explanation [click here](#)

-

# $\beta$ -adrenoceptor blockers


The elevated adrenergic activity in chronic heart failure patients cause structural remodeling of the heart (cardiac dilatation & hypertrophy)

Generation	Second generation	Third generation	
Drug	Eg: Bisoprolol Metoprolol	Eg: Carvedilol	Eg: Nebivolol
	Cardioselective ( $\beta$ 1-receptor)	$\beta$ -1 receptor blocker + have additional vasodilator action (a blocking effect).	
		Non selective vasodilators (alpha and beta blocker) ( $\alpha$ 1, $\beta$ 2) (selective $\alpha$ and non selective $\beta$ -blocker).	$\beta$ 1- selective with vasodilating properties not mediated by a blockade due to increase in endothelial release of NO via induction of eNOS.
M.O.A in HF	<p>1. Attenuate/slow down cardiac remodeling.</p> <p>2. Slow heart rate, which allows the left ventricle to fill more completely.</p> <p><b>3. Decrease renin release</b>  <b>Important</b></p> <p><i>57:41 R&gt;B</i></p> <p>→ reduce mortality &amp; morbidity of patients with HF.</p>		
Use	<p>- Reduce the progression of chronic heart failure. <b>For stable patient.</b></p> <p>- NOT used in acute heart failure.</p>		

# New Drugs for Heart Failure:

## 1-Natriuretic peptides

Drug	Nesiritide
<b>Definition</b>	<p>- A purified preparation of human BNP, manufactured by recombinant DNA technology</p> <p>- BNP is a hormone secreted by cardiomyocyte in the heart ventricles in response to stretch caused by increased ventricular blood.</p> <p>- Elevated BNP and ANP are associated with advanced HF (compensatory mechanism in HF)</p>
<b>M.O.A</b>	<ul style="list-style-type: none"><li>- Physiological effects of ANP and BNP:<ul style="list-style-type: none"><li>- Vasodilation.</li><li>- Natriuresis (excretion of sodium in urine)</li></ul></li><li>- Inhibition of RAAS (inhibitory effects on renin secretion, inhibit the action of ANG II &amp; aldosterone).</li><li>- ↑ cyclic-GMP in vascular smooth muscle leading to:<ul style="list-style-type: none"><li>• smooth muscle relaxation (vasodilation).</li><li>• reduction of preload and afterload.</li></ul></li></ul>
<b>Uses</b>	<p>Indicated (IV) for the treatment of patients with (ADHF “acute decompensated heart failure”) who have dyspnea at rest or with minimal activity (not given in stable cases).</p>



## 2-Calcium sensitisers

Drug	Levosimendan
<b>M.O.A</b>	<ul style="list-style-type: none"><li>- Calcium sensitization (improves cardiac contractility Without increasing oxygen consumption) (no extra work on heart).</li><li>- Potassium-ATP channel opening (cause vasodilation, improving blood flow to vital organs).<ul style="list-style-type: none"><li>- These effects reduce the risk of worsening ADHF or death compared with dobutamine.</li></ul></li></ul>
<b>uses</b>	<p>Used in management of ADHF (not given in stable cases).</p>



# Management of heart failure:



## Management of Chronic Heart Failure (Non-pharmacological).

- Reduce workload of the heart ex:
  - A) Limit patient activity.
  - b) Reduce weight
  - C) Control hypertension
- Restrict sodium because  $\uparrow$  sodium  $\rightarrow$   $\uparrow$  BP  $\rightarrow$   $\uparrow$  edema.
- Stop smoking.

## Management of acute heart failure

ADHF is a common and potentially serious cause of respiratory distress.

Acute Decompensated Heart failure (ADHF): A sudden worsening of signs and symptoms of heart failure, which typically includes:

- difficulty breathing (dyspnea)
- leg or feet swelling
- 3- fatigue



## Congestive heart failure in black patients

Hydralazine (Arterial Dilator)/ isosorbide dinitrate (venodilators) **fixed dose combination**.


• FDA approved to add to standard therapy for black Americans with Congestive heart failure.

(due to poor response to ACE inhibitors).

• Should be considered for patient intolerant to ACE inhibitor & ARBs due to **renal dysfunction**.



# Heart Failure Functional Classification and Management of Chronic heart failure:



◆ The severity of heart failure is usually described according to a scale devised by the New York Heart Association (NYHA):

NYHA Class:		I	II	III	IV
Functional classification	Symptoms	Cardiac disease, but no symptoms & no limitation in ordinary physical activity, eg: no shortness of breath when walking, climbing stairs etc. -symptoms occur only with greater than ordinary exercise.	Mild symptoms (mild shortness of breath &/or angina), slight limitation during activity which result in fatigue and palpitations.	Marked limitation in activity due to symptoms (fatigue, etc), even during less-than ordinary activity, eg: walking short distance (20-100m). Comfortable only at rest (no symptoms).	Severe limitation, experiences symptoms even while at rest. Mostly bed bound patients.
	for survival (morbidity)	Continue ACE inhibitor/ARB if ACE inhibitor intolerant, continue aldosterone antagonist If post-MI and add beta-blocker if post MI used as prophylaxis so it doesn't get worse	ACE inhibitor as first line treatment/ARB if ACE inhibitor intolerant add beta blocker and aldosterone antagonist if post-MI.	ACE inhibitor + ARB or ARB alone if ACE intolerant Beta blocker Add aldosterone antagonist	-Continue ACE inhibitor/ARB -Beta blocker -aldosterone antagonist
MManagement of chronic heart failure	for symptoms	Reduce/stop diuretic	+/- diuretic depending on fluid retention	+diuretic +Digitalis if still symptomatic	+Diuretic +Digitalis +Consider temporary inotropic support

# EXTRA SLIDE

## At Risk for Heart Failure

### STAGE A

At high risk for HF but without structural heart disease or symptoms of HF

e.g., Patients with:

- HTN
- Atherosclerotic disease
- DM
- Obesity
- Metabolic syndrome

or

Patients:

- Using cardiotoxins
- With family history of cardiomyopathy

Structural heart disease

### THERAPY

- Goals
- Heart healthy lifestyle
  - Prevent vascular, coronary disease
  - Prevent LV structural abnormalities

- Drugs
- ACEI or ARB in appropriate patients for vascular disease or DM
  - Statins as appropriate

### STAGE B

Structural heart disease but without signs or symptoms of HF

e.g., Patients with:

- Previous MI
- LV remodeling including LVH and low EF
- Asymptomatic valvular disease

### THERAPY

- Goals
- Prevent HF symptoms
  - Prevent further cardiac remodeling

- Drugs
- ACEI or ARB as appropriate
  - Beta blockers as appropriate

- In selected patients:
- ICD
  - Revascularization or valvular surgery as appropriate

Development of symptoms of HF

### STAGE C

Structural heart disease with prior or current symptoms of HF

e.g., Patients with:

- Known structural heart disease and
- HF signs and symptoms

HFpEF

### THERAPY

- Goals
- Control symptoms
  - Improve HRQOL
  - Prevent hospitalization
  - Prevent mortality

- Strategies
- Identification of comorbidities

- Treatment
- Diuretics to relieve symptoms of congestion
  - Follow guideline driven indications for comorbidities, e.g., HTN, AF, CAD, DM

HF/rEF

### THERAPY

- Goals
- Control symptoms
  - Patient education
  - Prevent hospitalization
  - Prevent mortality

- Drugs for routine use
- Diuretics for fluid retention
  - ACEI or ARB
  - Beta blockers
  - Aldosterone antagonists

- Drugs for use in selected patients...
- Hydralazine/isosorbide dinitrate
  - ACEI and ARB
  - Digitalis

- In selected patients:
- CRT
  - ICD
  - Revascularization or valvular surgery as appropriate

## Heart Failure

### STAGE D

Refractory HF

e.g., Patients with:

- Marked HF symptoms at rest
- Recurrent hospitalizations despite GDMT

### THERAPY

- Goals
- Control symptoms
  - Improve HRQOL
  - Reduce hospital readmissions
  - Establish patient's end-of-life goals

- Options
- Advanced care measures
  - Heart transplant
  - Chronic inotropes
  - Temporary or permanent MCS
  - Experimental surgery or drugs
  - Palliative care and hospice
  - ICD deactivation

“ study smarter , not harder “

## Active recall



For Anki flash cards click the icon




Take active quizzes in our team channel  
to test your understanding.



click the icon to get free flash cards

## summary



# MCQs

1

What is the primary indication for the use of digoxin in the treatment of heart failure?

A

Preserving sinus rhythm and atrial fibrillation

B

Reducing blood pressure in hypertension

C

Improving myocardial contractility

D

Preventing ventricular arrhythmias

2

Which of the following electrolyte disturbances increases the risk of Digoxin's toxicity?

A

Hypocalcemia

B

Hypomagnesemia

C

Hyponatremia

D

Hyperkalemia

3

ACE inhibitors can cause dry cough in some patients. This ADR is due to?

**Important**

A

Histamine release

B

Increased sympathetic activity

C

Direct irritation of respiratory tract

D

Bradykinin accumulation

4

Which of these drugs could cause dry cough?

A

Procainamide

B

Losartan

C

Verapamil

D

Captopril



# MCQs

5

Which of the following is an ADR in loop diuretics and thiazide drugs?

A Hypokalemia

B Hyperkalemia

C Hypoglycemia

D Hyperglycemia

6

Which of the following drugs increases contractility and causes vasodilation?

A Milrinone

B Ranolazine

C Niacin

D Adenosine

7

All of the following are ADRs of digoxin except?

A Diarrhea

B Bigeminal rhythm

C visual disturbances

D Fluid discoloration

8

What is used when the main symptom is rapid fatigue due to low cardiac output?

A Hydralazine

B Nitroglycerine

C Digoxin

D Spirolactone

# MCQs

*Important*

9

Which of the following causes Hypercalcemia

*Important*

A

Digoxin

B

Chlorothiazide

C

Bisoprolol

D

Captopril

10

Which of the following causes Hyperkalemia

*Important*

A

Milrinone

B

Ranolazine

C

Niacin

D

K<sup>+</sup> sparing diuretics

11

Patient presented to the ER with Pulmonary Edema. Which of the following drugs is considered First Line Therapy for control of edema

*Important*

A

Diuretics

B

Beta Blockers

C

Digitalis

D

ACE Inhibitors

12

Which of the following drugs decrease renin release

*Important*

A

Captopril

B

Losartan

C

Carvedilol

D

Digoxin

# SAQs

**1** What categories are considered as the first line agents used to treat heart failure? And mention 2 examples for each .

◆ Diuretics+ ACEIs  
(examples in slide 6)

**2** A 53 year old patient came to the ER with acute heart failure .Milrinone was given to manage his case.Discuss its MOA,its role on preload and/or afterload and the route of administration used.

◆ Slide 17

**3** A 62-year-old male patient with a history of hypertension and diabetes mellitus presents to the primary care clinic for a routine follow-up visit. His blood pressure readings have been consistently elevated, despite being on a thiazide diuretic. His current blood pressure is 150/90 mmHg. The doctor considered ACEIs as an option for management.List 4 ADRs that patient should be aware of .

◆ Slide 13

**4** A 54 year old has severe dyspnea due to pulmonary congestion and edema along with severe heart failure. Venodilators were given to relief his symptoms. Mention 2 drugs that can be used with their MOA and route of administration .

◆ Slide 10



# Lecture Done by :

**Shoug Albattah**

**Mohammed Almurshid**

**Haya Alkhelaiwi**

**Abdulmalik Aldafas**

**Basmah Alghamdi**

# Team Leaders :

**Ritaj Alsubaie**

**Ali Al Abdulazem**

**Sarah Alajmy**

**Waleed Alanazi**

**Abdullah Balbaid**

✉ Contact us at : [pharmacology.444ksu@gmail.com](mailto:pharmacology.444ksu@gmail.com)